-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Wind data shows that as of the close of September 17, since September, the agency has conducted 753 surveys on 461 listed companies.
From the perspective of industry classification, the electronics, industrial machinery, chemical and pharmaceutical industries are particularly favored.
92, 47, 38 and 37 listed companies have received institutional surveys
.
From the 37 listed pharmaceutical companies that have received institutional research, many companies have received intensive research from hundreds of institutions
.
For example, Aibo get 298 medical research institutions get together, including Wells Fargo Funds, Hillhouse Capital, China Universal Fund, Harvest Fund, Invesco Great Wall Fund, Gao Yi assets, Hing permit the Global Fund, E Fund, Central Fund
.
During the investigation process, the institution attracted much attention to the company's research and development, future layout and other issues
.
In terms of product layout, Aibo Medical said that the company's R&D pipeline is very rich.
When product R&D reaches a certain stage, the company will disclose it in regular reports
.
As a R&D and innovative company, Aibo Medical will continue to do a good job of products and serve patients, doctors and distributors
.
The company’s medium and long-term development goal is still to develop a full range of ophthalmic medical products, including implantable ophthalmic consumables, surgical instruments, surgical equipment, optoelectronic products, ophthalmic preparations and other products, covering cataracts, refractive errors, glaucoma, fundus lesions and many other fields
.
In addition, many pharmaceutical companies have received surveys from more than 20 institutions
.
For example, on September 17, Jianfan Biological disclosed the record of investor relations activities and showed that more than 70 investors including Guangfa Fund, CITIC Industrial Fund, Essence Securities, Industrial Securities, CITIC Construction Investment, and Huatai Securities participated in the survey
.
In the interactive session, the organization paid close attention to issues such as the future development plan of Jianfan Biology in the international market, the future layout of the company's nephrology products in the hospital, and how to deal with the risks of centralized procurement.
.
Among them, on the issue of centralized procurement, the company predicts that the company’s products will not be included in the national centralized procurement scope in the short term.
In the long run, the company is also actively responding to centralized procurement risks at the strategic and tactical levels.
In the past few years, we have continued to exert efforts in the fields of severe liver disease, critical illness, and overseas markets, and continue to increase the proportion of business; at the strategic level, the company believes that the number of patients using hemoperfusion will greatly increase, and the frequency of use will also increase.
The company’s products have 3 A heavy research support
.
For another example, on September 5, Fuxiang Pharmaceutical issued an announcement that the company recently accepted investigations from 64 institutions
.
The organization mainly focuses on the company's Lingfu Pharmaceutical Research Institute, core advantages, and overall development strategy
.
Fuxiang Pharmaceuticals stated that the company has always adhered to the vertical integration development strategy of "pharmaceutical intermediates-raw materials-preparations" and is driven by innovative development
.
In recent years, the company has continuously implemented its development strategy through acquisitions and refinancing
.
In addition, Jingxin Pharmaceutical has received surveys from 22 institutions including Zhongtai Securities, Kaiyuan Securities, and AVIC Securities within the month.
The participating institutions have an overview of the company’s online e-commerce layout, innovative drug layout in the field of mental nerves and cardiovascular and cerebrovascular.
Questions were asked about the development plan for the next year and the risk of R&D under a large amount of R&D investment
.
Regarding the development plan for the next year, Jingxin Pharmaceutical said that the company's development momentum comes from the steady development of its main business: the risk of centralized procurement and price reduction of finished drugs and statin products has basically landed, and will become stable with the expansion of the out-of-hospital market; With the growth of self-employed teams and the growth of pharmaceutical e-commerce, the mental nerve and digestive fields continue to maintain a good growth trend
.
The certification of APIs in overseas markets is progressing steadily, and overseas high-end markets are expected to break through growth
.
The medical device board (Shenzhen Jufeng) increased its new business and expanded its domestic and overseas markets, maintaining a steady growth trend
.
From the perspective of industry classification, the electronics, industrial machinery, chemical and pharmaceutical industries are particularly favored.
92, 47, 38 and 37 listed companies have received institutional surveys
.
From the 37 listed pharmaceutical companies that have received institutional research, many companies have received intensive research from hundreds of institutions
.
For example, Aibo get 298 medical research institutions get together, including Wells Fargo Funds, Hillhouse Capital, China Universal Fund, Harvest Fund, Invesco Great Wall Fund, Gao Yi assets, Hing permit the Global Fund, E Fund, Central Fund
.
During the investigation process, the institution attracted much attention to the company's research and development, future layout and other issues
.
In terms of product layout, Aibo Medical said that the company's R&D pipeline is very rich.
When product R&D reaches a certain stage, the company will disclose it in regular reports
.
As a R&D and innovative company, Aibo Medical will continue to do a good job of products and serve patients, doctors and distributors
.
The company’s medium and long-term development goal is still to develop a full range of ophthalmic medical products, including implantable ophthalmic consumables, surgical instruments, surgical equipment, optoelectronic products, ophthalmic preparations and other products, covering cataracts, refractive errors, glaucoma, fundus lesions and many other fields
.
In addition, many pharmaceutical companies have received surveys from more than 20 institutions
.
For example, on September 17, Jianfan Biological disclosed the record of investor relations activities and showed that more than 70 investors including Guangfa Fund, CITIC Industrial Fund, Essence Securities, Industrial Securities, CITIC Construction Investment, and Huatai Securities participated in the survey
.
In the interactive session, the organization paid close attention to issues such as the future development plan of Jianfan Biology in the international market, the future layout of the company's nephrology products in the hospital, and how to deal with the risks of centralized procurement.
.
Among them, on the issue of centralized procurement, the company predicts that the company’s products will not be included in the national centralized procurement scope in the short term.
In the long run, the company is also actively responding to centralized procurement risks at the strategic and tactical levels.
In the past few years, we have continued to exert efforts in the fields of severe liver disease, critical illness, and overseas markets, and continue to increase the proportion of business; at the strategic level, the company believes that the number of patients using hemoperfusion will greatly increase, and the frequency of use will also increase.
The company’s products have 3 A heavy research support
.
For another example, on September 5, Fuxiang Pharmaceutical issued an announcement that the company recently accepted investigations from 64 institutions
.
The organization mainly focuses on the company's Lingfu Pharmaceutical Research Institute, core advantages, and overall development strategy
.
Fuxiang Pharmaceuticals stated that the company has always adhered to the vertical integration development strategy of "pharmaceutical intermediates-raw materials-preparations" and is driven by innovative development
.
In recent years, the company has continuously implemented its development strategy through acquisitions and refinancing
.
In addition, Jingxin Pharmaceutical has received surveys from 22 institutions including Zhongtai Securities, Kaiyuan Securities, and AVIC Securities within the month.
The participating institutions have an overview of the company’s online e-commerce layout, innovative drug layout in the field of mental nerves and cardiovascular and cerebrovascular.
Questions were asked about the development plan for the next year and the risk of R&D under a large amount of R&D investment
.
Regarding the development plan for the next year, Jingxin Pharmaceutical said that the company's development momentum comes from the steady development of its main business: the risk of centralized procurement and price reduction of finished drugs and statin products has basically landed, and will become stable with the expansion of the out-of-hospital market; With the growth of self-employed teams and the growth of pharmaceutical e-commerce, the mental nerve and digestive fields continue to maintain a good growth trend
.
The certification of APIs in overseas markets is progressing steadily, and overseas high-end markets are expected to break through growth
.
The medical device board (Shenzhen Jufeng) increased its new business and expanded its domestic and overseas markets, maintaining a steady growth trend
.
